American journal of clinical pathology最新文献_第2页

Blood banking services in critical access hospitals in Kansas: A laboratory perspective.

IF 2.3 4区医学

American journal of clinical pathology Pub Date : 2024-12-20 DOI: 10.1093/ajcp/aqae169

Letycia Nuñez-Argote, Alexandra Corns, Robert Moser

{"title":"Blood banking services in critical access hospitals in Kansas: A laboratory perspective.","authors":"Letycia Nuñez-Argote, Alexandra Corns, Robert Moser","doi":"10.1093/ajcp/aqae169","DOIUrl":"https://doi.org/10.1093/ajcp/aqae169","url":null,"abstract":"Objectives: To investigate the resource capacity for blood banking in critical access hospitals (CAHs) in Kansas and the experiences of medical laboratory personnel working in them.Methods: An electronic survey was implemented to record data from all 82 CAHs in Kansas between May and July 2023. The distance between hospitals with no blood bank services and commercial blood banks was calculated.Results: Only 63.4% of Kansas CAHs located in nonmetropolitan counties reported access to 24/7 blood bank services. In 12.2% of laboratories with 5 or fewer workers, there were no staff proficient in blood bank testing. While 72% of laboratories could perform type and screen and crossmatching, many lacked antibody identification capacity. Only 2 hospitals had the capacity to transfuse packed red blood cells, plasma, and platelets simultaneously if needed, with 20.6% of nonmetropolitan hospitals holding no blood products in inventory.Conclusions: The blood banking capacity of CAHs in Kansas is influenced by the lack of workforce availability and training, reduced availability of blood products, and distance from facilities where blood is processed. Solutions tailored to the unique rural environment are needed to ensure adequate access to blood for patients.","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142862579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trop-2 and Ephrin B2 expression in urothelial carcinoma with divergent differentiation and aggressive urothelial carcinoma subtypes.

IF 2.3 4区医学

American journal of clinical pathology Pub Date : 2024-12-20 DOI: 10.1093/ajcp/aqae161

Katherine B Case, Dylan J Martini, Melad N Dababneh, Samuel Bidot, Bassel Nazha, Jacqueline Brown, Shreyas Joshi, Vikram Narayan, Vaunita Parihar, Faisal Saeed, Mehmet Asim Bilen, Lara R Harik

{"title":"Trop-2 and Ephrin B2 expression in urothelial carcinoma with divergent differentiation and aggressive urothelial carcinoma subtypes.","authors":"Katherine B Case, Dylan J Martini, Melad N Dababneh, Samuel Bidot, Bassel Nazha, Jacqueline Brown, Shreyas Joshi, Vikram Narayan, Vaunita Parihar, Faisal Saeed, Mehmet Asim Bilen, Lara R Harik","doi":"10.1093/ajcp/aqae161","DOIUrl":"https://doi.org/10.1093/ajcp/aqae161","url":null,"abstract":"Objectives: Urothelial carcinomas (UCs) encompass a heterogeneous group of tumors. Several histopathologic features are associated with poor clinical outcomes and limited treatment options. With new rising therapeutic modalities, we aimed to determine the pattern of expression of Trop-2 and ephrin B2 in UC with aggressive subtype histology and/or divergent differentiation (SH/DD).Methods: We performed a retrospective analysis of 113 UC samples with SH/DD at our institution from 2011 to 2021. Immunohistochemical staining for Trop-2 and ephrin B2 expression was performed on all cases. Expression was determined by the percentage of samples with a moderate or strong H-score.Results: Our results show Trop-2 expression was the highest in squamous cell carcinoma and UC with squamous differentiation, adenocarcinoma and UC with glandular differentiation, and plasmacytoid subtype, while ephrin B2 expression was highest in adenocarcinoma, UC with glandular differentiation, and small cell carcinoma.Conclusions: Expression of Trop-2 and ephrin B2 may demonstrate therapeutic possibilities for patients with SH/DD, who usually have limited treatment options, particularly in small cell carcinoma, in which few targets have been identified. Clinical trials to investigate the efficacy of these novel treatments are warranted.","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142869280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How I diagnose high-grade B-cell lymphoma. 我是如何诊断高级别 B 细胞淋巴瘤的？

IF 2.3 4区医学

American journal of clinical pathology Pub Date : 2024-12-17 DOI: 10.1093/ajcp/aqae158

Erika M Moore, Sarah E Gibson

{"title":"How I diagnose high-grade B-cell lymphoma.","authors":"Erika M Moore, Sarah E Gibson","doi":"10.1093/ajcp/aqae158","DOIUrl":"https://doi.org/10.1093/ajcp/aqae158","url":null,"abstract":"Objectives: High-grade B-cell lymphoma (HGBL), introduced in the 2016 World Health Organization (WHO) revised fourth edition classification, included cases defined by MYC and BCL2 and/or BCL6 rearrangements or by high-grade morphology. Diagnostic criteria and nomenclature for these lymphomas were refined in the 2022 WHO fifth edition (WHO-5) classification and International Consensus Classification (ICC). This review describes our approach to the diagnosis of HGBL.Methods: Two cases are presented illustrating how we diagnose HGBL, including 1 case harboring MYC and BCL6 rearrangements and a second showing TdT expression in an HGBL with MYC and BCL2 rearrangements. The ways in which these cases are distinguished from other lymphomas with high-grade features and the appropriate nomenclature using WHO-5 and ICC classifications are emphasized.Results: An HGBL diagnosis requires integration of morphology, immunophenotype, and genetics and exclusion of other lymphomas with high-grade morphology, including Burkitt lymphoma, B-lymphoblastic leukemia/lymphoma (B-LBL/ALL), and blastoid mantle cell lymphoma. A diagnosis of HGBL/large B-cell lymphoma with 11q aberration should also be considered in certain patient populations.Conclusions: High-grade B-cell lymphomas are subclassified based on morphologic and genetic features. There are differences in the nomenclature and definition of these lymphomas in the WHO-5 and ICC classifications. Distinguishing HGBLs from other mature B-cell lymphomas and B-LBL/ALL is critical so that patients receive appropriate treatment.","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142845592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Use of anatomic pathology tools in global oncology outreach.

IF 2.3 4区医学

American journal of clinical pathology Pub Date : 2024-12-07 DOI: 10.1093/ajcp/aqae134

Harm Veerkamp, Cary Adams

引用次数: 0

Survey of anatomic and clinical pathology services and infrastructure in Nigeria.

IF 2.3 4区医学

American journal of clinical pathology Pub Date : 2024-12-07 DOI: 10.1093/ajcp/aqae156

Jonathan Tucci, Jeremy W Jacobs, Zainab U Ibrahim, Aminu A Yusuf, Ali Bala Umar, Danny A Milner, Quentin Eichbaum

{"title":"Survey of anatomic and clinical pathology services and infrastructure in Nigeria.","authors":"Jonathan Tucci, Jeremy W Jacobs, Zainab U Ibrahim, Aminu A Yusuf, Ali Bala Umar, Danny A Milner, Quentin Eichbaum","doi":"10.1093/ajcp/aqae156","DOIUrl":"https://doi.org/10.1093/ajcp/aqae156","url":null,"abstract":"Objectives: The paucity of data regarding the availability and extent of diagnostic medical services across sub-Saharan Africa hinders appropriate allocation of resources to improve health care in these regions. We assessed anatomic pathology (AP) and clinical pathology (CP) services in Nigeria, one of the most populous and fastest-growing countries in the world.Methods: Two individual surveys (AP focused and CP focused) were developed by subject matter experts and administered to individuals involved in pathology and laboratory medicine diagnostic services at hospitals and laboratories across Nigeria between June and August 2022 using the American Society for Clinical Pathology email listserv.Results: A total of 75 responses (29 AP and 46 CP) were received from 48 unique laboratories. Twenty-four sites provided AP services and 35 provided CP services. Eleven respondents performed both AP and CP services. Among AP services, basic surgical and cytopathology capabilities were available at most sites; however, the availability of automated technologies (eg, automated sample processing and staining) was more variable. Advanced diagnostic techniques, (eg, immunohistochemistry, human papillomavirus testing, molecular diagnostics) were rarely performed. The most frequently available CP services included hematology, microbiology, and chemistry. Microbiology services appeared to be among the most robust laboratory medicine services, particularly parasitology and bacteriology testing. Similar to AP services, more advanced diagnostic assays, such as flow cytometry, cytogenetics, and molecular testing, were largely unavailable.Conclusions: These findings augment earlier studies and identify gaps that should be prioritized from a policy perspective to improve medical services and the overall health care infrastructure in Nigeria.","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142805970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Career pathways into the medical laboratory workforce: Education, exposures, and motivations. 进入医学实验室工作队伍的职业途径：教育、接触和动机。

IF 2.3 4区医学

American journal of clinical pathology Pub Date : 2024-12-06 DOI: 10.1093/ajcp/aqae151

Grace A Guenther, Shahida F Shahrir, Susan M Skillman, Iman Kundu, Edna Garcia, Bianca K Frogner

{"title":"Career pathways into the medical laboratory workforce: Education, exposures, and motivations.","authors":"Grace A Guenther, Shahida F Shahrir, Susan M Skillman, Iman Kundu, Edna Garcia, Bianca K Frogner","doi":"10.1093/ajcp/aqae151","DOIUrl":"https://doi.org/10.1093/ajcp/aqae151","url":null,"abstract":"Objectives: The goal of this study was to investigate career pathways into the medical laboratory workforce by examining medical laboratory scientists, medical laboratory technicians, histotechnologists, histotechnicians, cytologists, and phlebotomists.Methods: We collected data through an anonymous online survey (May-June 2023) from a convenience sample of medical laboratory professionals in the United States (N = 1243). We performed descriptive analyses of demographics, current employment characteristics, educational and training history, career exposures, motivations, movement, and outlook (eg, job satisfaction, future career plans).Results: Findings show a diverse range of educational backgrounds and varying career pathways across occupations. A majority of respondents reported hearing about laboratory occupations from friends, family, co-workers, and acquaintances. At least one-third to nearly one-half of respondents had a family member with broader professional health care experience. Respondents viewed their jobs favorably, with at least 75% of respondents answering that they would recommend their occupation or another laboratory occupation.Conclusions: This study found overall positive job experiences and satisfaction, but career pathways into medical laboratory occupations are complex and often unclear. Organizations in the field are undertaking promotional efforts to increase the visibility of these occupations. Future research is needed to monitor and evaluate these efforts.","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142826968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TRPS1 is a useful marker in differentiating metastatic breast carcinoma from pancreatic adenocarcinoma in fine-needle aspiration specimens.

IF 2.3 4区医学

American journal of clinical pathology Pub Date : 2024-12-05 DOI: 10.1093/ajcp/aqae155

Bahadir Yildiz, Jerome Jean-Gilles, Ellen J Giampoli, Sierra Kovar-Peltz, Qi Yang, Hiroshi Miyamoto, Ying Wang

{"title":"TRPS1 is a useful marker in differentiating metastatic breast carcinoma from pancreatic adenocarcinoma in fine-needle aspiration specimens.","authors":"Bahadir Yildiz, Jerome Jean-Gilles, Ellen J Giampoli, Sierra Kovar-Peltz, Qi Yang, Hiroshi Miyamoto, Ying Wang","doi":"10.1093/ajcp/aqae155","DOIUrl":"https://doi.org/10.1093/ajcp/aqae155","url":null,"abstract":"Objectives: Distinction of metastatic breast carcinoma (BC) to the pancreas from primary pancreatic adenocarcinoma (PAC) is essential but challenging. Breast carcinoma shares similar morphology and exhibits an overlapping immunohistochemistry (IHC) profile with PAC. We investigated the utility of recently reported trichorhinophalangeal syndrome type 1 (TRPS1) IHC in differentiating metastatic BC from PAC in fine-needle aspiration (FNA) specimens.Methods: We assessed consecutive patients of PAC (n = 49). Due to limited cases of metastatic BC to the pancreas (n = 3), cases of metastatic BC (n = 23) in various locations, including lymph node, lung, bone, or soft tissue, were included. Immunohistochemistry for TRPS1 was performed by using the cell blocks obtained from FNA. A quantitative score for TRPS1 expression was calculated by multiplying the intensity and the percentage of positive cells. Immunoreactivity scores were assigned as negative, low positive, intermediate positive, or high positive.Results: In 49 PAC cases, 47 (95.9%) exhibited negative while 2 (4.1%) exhibited low positive TRPS1 expression. However, TRPS1 expression was high positive in 23 (88.0%) of 26 metastatic BC cases, including 10 (83.3%) of 12 triple-negative BC (TNBC) and 13 (92.9%) of 14 non-TNBC cases.Conclusions: Our results suggest that TRPS1 IHC represents a highly accurate and reliable method for differentiating metastatic BC from PAC.","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating the potential for iodinated radiocontrast agents to interfere with ADAMTS13 activity testing via fluorescence resonance energy transfer methodology. 通过荧光共振能量转移方法评估碘化放射造影剂干扰 ADAMTS13 活性检测的可能性。

IF 2.3 4区医学

American journal of clinical pathology Pub Date : 2024-12-05 DOI: 10.1093/ajcp/aqae160

Jeremy W Jacobs, Melissa S Stuart, Julie I Tange, Rachel R Leger, Aneel A Ashrani, Dong Chen, Rajiv K Pruthi, Meera Sridharan, Jansen N Seheult

{"title":"Evaluating the potential for iodinated radiocontrast agents to interfere with ADAMTS13 activity testing via fluorescence resonance energy transfer methodology.","authors":"Jeremy W Jacobs, Melissa S Stuart, Julie I Tange, Rachel R Leger, Aneel A Ashrani, Dong Chen, Rajiv K Pruthi, Meera Sridharan, Jansen N Seheult","doi":"10.1093/ajcp/aqae160","DOIUrl":"https://doi.org/10.1093/ajcp/aqae160","url":null,"abstract":"Objectives: Fluorescence resonance energy transfer (FRET)-based ADAMTS13 activity assays are critical for the diagnosis of thrombotic thrombocytopenic purpura. However, these assays are susceptible to interference. As iodide has been suggested to interfere in laboratory testing via fluorophore quenching or promotion, we aimed to determine whether iodinated contrast (Omnipaque) interferes with the ATS-13 ADAMTS13 Activity Assay 2.0.Methods: We evaluated the excitation, emission, and absorbance spectrum of Omnipaque alone and spiked in patient plasma with known ADAMTS13 activity and ADAMTS13 activity on Omnipaque alone, an abnormal control of patient plasma previously observed to display elevated baseline relative fluorescent units, and variable concentrations of patient plasma with known ADAMTS13 activity spiked with Omnipaque.Results: No atypical fluorescent peaks were observed on any sample (Omnipaque alone or spiked in plasma) between 250 and 700 nm. There was no difference in the mean ADAMTS13 activity among the various concentrations of plasma spiked with Omnipaque or plasma spiked with saline.Conclusions: Iodinated contrast does not appear to interfere-either via spectral overlap of the fluorophore or through physiologic inhibition of the ADAMTS13 enzyme-with ADAMTS13 activity FRET-based assays based on the findings from this in vitro analysis. Delaying sample collection for ADAMTS13 activity testing from suspected patients with thrombotic thrombocytopenic purpura following administration of iodinated radiocontrast agents is not necessary, and recent contrast administration should not yield erroneous ADAMTS13 activity results.","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142826969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: Escalation process of critical values when these cannot be communicated on first attempt: A hospital-wide process improvement project. 更正：当关键值无法在首次尝试时传达时，升级关键值的流程：全院流程改进项目。

IF 2.3 4区医学

American journal of clinical pathology Pub Date : 2024-11-19 DOI: 10.1093/ajcp/aqae157

引用次数: 0

Correction to: Pilomatrix-like breast carcinoma: A mammary analog of pilomatrix-like high-grade endometrioid carcinoma (PiMHEC). 更正：皮瘤样乳腺癌：皮瘤样高级别子宫内膜样癌（PiMHEC）的乳腺类似物。

IF 2.3 4区医学

American journal of clinical pathology Pub Date : 2024-11-14 DOI: 10.1093/ajcp/aqae154

引用次数: 0